Latest Advances in the Treatment of Heart Failure and LVAD as a Heart Transplantation Alternative

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • CPE: 1.00
    • Other: 1.00
  • Cost: Free
  • Release: Nov 29, 2016
  • Expires: Nov 28, 2019
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)


Maya E.  Guglin Maya E. Guglin, MD, PhD
Professor, Medicine
Director, Mechanical Circulatory Support
UK Gill Heart & Vascular Institute
Lexington, Kentucky

Navin Rajagopalan Navin Rajagopalan, MD
Associate Professor, Medicine
University of Kentucky College of Medicine
Medical Director, Cardiac Transplantation
UK HealthCare
Lexington, Kentucky

Needs Statement

Heart failure is a major health problem in the United States leading to frequent hospitalizations and high mortality.  According to the Centers for Disease Control and Prevention, approximately 5.1 million people in the United States have heart failure and about half of people who develop heart failure die within five years of diagnosis.  In addition, heart failure costs the nation an estimated $32 billion each year, which includes the cost of health care services, medications to treat heart failure, and missed days of work.  Optimal medical therapy for heart failure continues to evolve.  In addition, newer developments, such as ventricular assist devices, show promise in the treatment of end-stage heart failure.  The purpose of this presentation is to provide information about new developments in the medical treatment of heart failure; explain the indications and contraindications of new medical therapies for heart failure; recognize the optimal timing for referral for advanced therapies in heart failure; explain the rationale for LVAD placement; identify the pros and cons of heart transplant versus LVAD implantation; and explain the candidate selection process for LVAD implantation.

Target Audience

Physicians, Physician Assistants, Pharmacists, Health Administrators, Medical Assistants/Technicians, Cardiovascular Technicians, Nurses, Nurse Practitioners, Clinical Researchers


Upon completion of this activity, you will be able to:

  1. Describe new pharmacologic advances in the treatment of chronic systolic heart failure. 
  2. Explain the indications and contraindications to new medical therapies for heart failure.
  3. Identify the optimal timing for referral for advances therapies in heart failure.
  4. Explain the rationale for LVAD placement. 
  5. Discuss the pros and cons of transplant versus LVAD. 
  6. Outline the candidate selection process for LVAD implantation


The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Practice-based learning and improvement
  • Systems-based practice

ACPEThe University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UAN 0022-9999-16-124-H01-P and will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

Faculty Disclosure

No speakers, authors, planners have any relevant financial relationships to disclose. 

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation. 


In collaboration with UK Transplant Center.

CE Content Concerns


Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504


  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.